- Conditions
- RSV Infection
- Interventions
- EDP-323, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1992
of 4,633
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Adults
- Interventions
- Prednisone, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Placebo/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 133
- States / cities
- Fairhope, Alabama • Sun City, Arizona • Tucson, Arizona + 117 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- GSK189075, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Socioemotional Aging
- Interventions
- Oxytocin Spray, Placebo Spray
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Diabetes Prevention
- Interventions
- Dose 1, Dose 2, Dose 0, Dose 3, Dose 4, Dose 5, Dose 6
- Dietary Supplement
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Trigeminal Neuropathic Pain
- Interventions
- PET Scans, transcranial direct current stimulation (tDCS), MRI, sham tDCS (prior to real tDCS)
- Procedure · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Healthy
- Interventions
- MTP-131 (Bendavia™)
- Drug
- Lead sponsor
- Mighty Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Depression, Anxiety, Major Depressive Disorder
- Interventions
- CYB003, Placebo
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Nabilone, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 21 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- ME1100 inhalation solution, ME1100 placebo inhalation solution
- Drug
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy Volunteers
- Interventions
- PF-04427429
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Influenza
- Interventions
- Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo
- Drug · Other
- Lead sponsor
- Autoimmune Technologies, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Spinal Cord Injuries
- Interventions
- 5-Hydroxytryptophan 100 MG, 5-Hydroxytryptophan, Carbidopa, Placebo
- Drug
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Missoula, Montana • Norfolk, Nebraska
- Conditions
- Healthy
- Interventions
- FosD, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Volunteers
- Interventions
- KINE-101, Placebo
- Drug
- Lead sponsor
- Kine Sciences Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 844 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 55
- States / cities
- Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more
- Conditions
- Healthy
- Interventions
- PF-06946860, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Steatohepatitis
- Interventions
- AZD7503
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more
- Conditions
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Interventions
- AH-008 for Injection, 150 mg, AH-008 for Injection, Placebo
- Drug
- Lead sponsor
- AnHorn Medicines Co. Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hepatitis C
- Interventions
- ABT-072, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Waukegan, Illinois
- Conditions
- Cocaine Use Disorder
- Interventions
- Phendimetrazine, Cocaine, Placebo
- Drug
- Lead sponsor
- William Stoops
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more